effects of high fio2 on post-ercp pancreatitis.

Conditions: Post-ERCP Pancreatitis

Summary: post-ercp pancreatitis is one of the most common complications accounting for substantial morbidity and mortality. the incidence of post-ercp pancreatitis (pep) has been studied in several large clinical trials and ranges from 1.6-15%. however most studies have demonstrated rates around 5%. this complication alone is estimated to cost the us healthcare around $150 million annually. to prevent this complication several pharmacological agents have been studied and no medication has been proved to be consistently effective in preventing this complications. cyclo-oxygenase, and phospholipase a2 pathways are believed to play an important role in the pathogenesis of acute pancreatitis and so non-steroidal anti-inflammatory drugs (nsaids) have been extensively studied in the prevention of post-ercp pancreatitis. one of the landmark studies done on prophylactic nsaids for pep showed that rectal indomethacin significantly reduce the incidence of pep (pep developed in 9.2% vs. 16.9% of indomethacin and placebo groups respectively). since then the use of rectal nsaids has become a standard chemo-prophylaxis for prevention of pep especially in high risk patients. however, newly published meta-analysis showed that the role of peri-procedural rectal indomethacin is doubtful in patients with average risk for pep. in this prospective randomized clinical study, we propose to study the effects of supplemental peri-operative oxygen on the incidence of pep. the effects of high oxygen fraction (fio2) has extensively been studied in reducing the incidence of surgical site infection, postoperative nausea, vomiting and to prevent postoperative atelectasis. changing the fio2 during a procedure can be a simple, inexpensive and low risk intervention to prevent post-procedure complications.

the study will be a prospective, parallel-group, randomized double blinded control study conducted at university of kentucky - chandler medical center. both the patient and the endoscopist will be blinded to the group assignment. permuted block randomization will be used to randomly allocate a participant to a treatment group that will maintain a balance across treatment groups. each block will have a specified number of randomly ordered treatment assignments. to assure randomization is blinded, randomization lists will be produced by the statistical team using varying block sizes of 100. group assignments will be kept in sealed, sequentially numbered envelopes until used. once patient is determined to be eligible, endoscopist will obtain consent and anesthetist will open the envelope which will assign patients either to group 1: 30% fio2 or group 2: 80% fio2. an anesthesia provider will administer fio2 to the patient throughout the procedure period. additional supplemental oxygen will be given to patients in either group at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter \> 92%. patients will be observed in the recovery area for at least 90 minutes after the procedure. patients who develop abdominal pain during the post-endoscopy period are admitted to the hospital and standard pancreatitis clinical care is provided. patients who are discharged after an uneventful ercp will be contacted by telephone within 5 days to capture delayed occurrence of pancreatitis. patients will again be contacted at 30 days to assess for delayed adverse events and to determine the severity of post-ercp pancreatitis, which is defined in part by the length of hospitalization for pancreatitis. patients who do not consent to be included in the study will receive the standard endoscopic treatment at the discretion of the therapeutic endoscopist. the endoscopic intervention will be conducted in the endoscopy suite on the third floor at the university of kentucky healthcare medical center in lexington, kentucky. if no additional endoscopic intervention is required, then the patient will be scheduled for subsequent follow up clinic visits. after the conclusion of the study, patients will continue to be followed as clinically necessary by either the same or another gastroenterologist. the patient has the right to withdraw consent to participate in the study at any time. the patient can be withdrawn from the study if they are not able to follow directions for study participation. if the patient decides to no longer take part in the study, their decision will have no effect on the medical care they will receive.

Eligibility criteria:
inclusion criteria: 1. patients undergoing ercp 2. 18 years and older 3. capable of giving consent for the procedure exclusion criteria: 1. unwillingness or inability to consent for the study 2. age less than 18 years 3. standard contraindications to ercp 4. acute pancreatitis within 72hrs prior to ercp 5. chronic calcific pancreatitis 6. pancreatic divisum 7. pancreatic malignancy 8. icu patients 9. patients on home oxygen at baseline. 10. incarcerated patients.